



Inaugural Symposium on **Kidney Transplantation in Plasma Cell Disorders**

SEPTEMBER 12, 2024

ZUCKERMAN RESEARCH CENTER
NEW YORK, NY



Memorial Sloan Kettering
Cancer Center

Overview

We're excited to present the inaugural symposium on renal transplantation in plasma cell disorders. This program unites multidisciplinary experts from Memorial Sloan Kettering Cancer Center and around the world, spanning specialties such as **hematology, nephrology, surgery, pathology, immunology, and bioethics.**

We'll explore critical topics pertaining to the evaluation and management of plasma cell dyscrasia patients being considered for kidney transplantation, including:

- Updates in Monoclonal Gammopathy of Renal Significance (MGRS) pathology and classification;
- The latest developments in clone-directed therapy and outcomes;
- Assessing depth of response;
- Updates on transplant biology and immunology;
- Complications of renal transplantation in patients with plasma cell disease; and
- Fair distribution of a scarce resource and role of living donor transplantation.

Additionally, this symposium will feature a **patient and clinician roundtable** discussion and a **workshop on best practices** for distinct disease entities.

Early discounted rates available through July 26.

msk.org/KidneyTransplantation



TARGET AUDIENCE

The symposium is intended for physicians, advanced practice providers, registered nurses, fellows, trainees, and other healthcare professionals interested in kidney transplantation for plasma cell disorders.

This symposium will be held **exclusively in person**, with no virtual attendance option available.

LEARNING OBJECTIVES

At the conclusion of this program, attendees will be able to:

- Describe the pathology and classification of the distinct subtypes of Monoclonal Gammopathy of Renal Significance (MGRS)
- Summarize the updates in treatment and outcome assessment in the common plasma cell dyscrasias including multiple myeloma, light chain amyloidosis and MIDD
- Review the methods for assessing depth of response in plasma cell disorders and their added value and limitations
- Explain critical components of transplant biology and immunology that inform renal transplant practice
- Describe common complications of renal transplantation and management
- Discuss barriers to access to renal transplantation, strategies improve more equitable distribution and the role of living donor transplantation



EXCLUSIVE DISCOUNT OFFER

We're excited to offer attendees of this symposium a special **\$75 discount** for the **2024 Onco-Nephrology Symposium**, scheduled for Friday and Saturday, **September 13—14**.

msk.org/Onco-Nephrology

Registration

Discounted registration is available for specific groups.

Access our Policy on Registration Discounts on the symposium website for more information.

Early Discounted Rates (valid through July 26)

- Physicians (MDs, PhDs, and DOs): \$200
- Advanced Practice Providers: \$150
- Nurses and Other Healthcare Providers: \$100
- Fellows, Residents, and Students: \$50 (non-refundable)
- Industry Professionals*: n/a
- MSK Employees: Complimentary

General Rates

- Physicians (MDs, PhDs, and DOs): \$250
- Advanced Practice Providers: \$200
- Nurses and Other Healthcare Providers: \$150
- Fellows, Residents, and Students: \$100 (non-refundable)
- Industry Professionals*: \$450
- MSK Employees: Complimentary

*An "industry professional" is defined as any individual, regardless of their profession type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company.

For details and registration, visit:

msk.org/KidneyTransplantation

SYMPOSIUM DIRECTOR



Heather J. Landau, MD

Director, Amyloidosis Program
Associate Attending, Bone Marrow Transplant
and Cellular Therapy Services
Memorial Sloan Kettering Cancer Center

SYMPOSIUM CO-DIRECTOR



Insara Jaffer Sathick, MBBS, MRCP

Assistant Attending, Renal Service
Memorial Sloan Kettering Cancer Center

SYMPOSIUM PLANNING COMMITTEE

Raymond Comenzo, MD

Director, Transfusion Services;
Director, John C. Davis Myeloma and Amyloid Program
Tufts Medical Center

Ann Deely

Patient Planner

Edgar A. Jaimes, MD

Chief, Renal Service
Memorial Sloan Kettering Cancer Center

Kenar Dinesh Jhaveri, MD

Associate Chief, Division of Kidney Diseases and Hypertension
Northwell Health;
Professor of Medicine
Zucker School of Medicine at Hofstra/Northwell

Sheron Latcha, MD

Program Director, Nephrology Fellowship;
Attending, Renal Service
Memorial Sloan Kettering Cancer Center

Nelson Leung, MD

Consultant, Division of Nephrology & Hypertension,
Department of Internal Medicine
Mayo Clinic

Naoka Murakami, MD, PhD

Assistant Professor of Medicine
Harvard Medical School / Brigham and Women's Hospital

Aisha Shaikh, MBBS

Associate Attending, Renal Service
Memorial Sloan Kettering Cancer Center

INVITED FACULTY**Syed Ali Husain, MD**

Assistant Professor of Medicine
Columbia University Medical Center

Oscar B. Lahoud, MD

Director, Strategy and Network Operations,
Perlmutter Cancer Center – Hematology/Oncology;
Section Chief, Hematology – NYU Brooklyn;
Clinical Associate Professor of Medicine,
NYU Grossman School of Medicine

Thangamani Muthukumar, MD, MS

Associate Professor of Medicine
Weill Cornell Medical College

Vinay Nair, DO

Associate Professor
Donald and Barbara Zucker School of Medicine at
Hofstra/Northwell

Vinita Sehgal, MD

Associate Professor of Medicine, Nephrology
Mount Sinai

Allison Webber, MD

Professor of Medicine
University of California San Francisco

MSK FACULTY

Hani Hassoun, MD

Attending, Myeloma Service

Sham Mailankody, MBBS

Associate Attending;
Clinical Director, Cellular Therapy Service;
Research Director, Myeloma Service

Sridevi Rajeeve, MD

Assistant Attending, Cellular Therapy and Myeloma Services

Mikhail Roshal, MD, PhD

Attending, Hematopathology Service

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

Schedule

THURSDAY, SEPTEMBER 12

8:00 AM Registration and Breakfast

8:55 AM **Introductory Remarks**
Heather J. Landau, MD

Introduction to Monoclonal Gammopathy of Renal Significance (MGRS)

MODERATOR: Heather J. Landau, MD

9:00 AM ***The Time is Now***
Insara Jaffer Sathick, MBBS, MRCP

9:20 AM **Updates in MGRS Pathology and Classification**
Nelson Leung, MD

Updates on Outcomes in Plasma Cell Disorders (PCD)

This session is designed to provide an updated overview of patients with PCDs who may be eligible for renal transplantation.

MODERATOR: TBA

9:50 AM **Myeloma**
Sridevi Rajeeve, MD

10:15 AM **Amyloid**
Raymond Comenzo, MD

10:35 AM **Monoclonal Immunoglobulin Deposition Disease (MIDD)**
Hani Hassoun, MD

10:55 AM **Depth of Response**
Mikhail Roshal, MD, PhD

11:15 AM **Panel Discussion and Q&A**

11:25 AM Break

Special Topics in Kidney Transplantation

MODERATOR: Edgar A. Jaimes, MD

11:40 AM **Transplant Biology, Immunology, and Management of Complications**
Thangamani Muthukumar, MD, MS

12:05 PM **Equity in Access and Addressing Disparities**
Syed Ali Husain, MD

Patient Round Table Discussion

A multidisciplinary panel of clinicians and experts will engage with patients, focusing on the challenges and opportunities for creating a collaborative patient experience.

12:30 PM	MODERATOR	Kenar Dinesh Jhaveri, MD
	PANELISTS	Ann Deely (Patient Planner) Oscar B. Lahoud, MD Vinay Nair, DO Vinita Sehgal, MD Allison Webber, MD

1:00 PM Lunch Break

Best Practices Workshop

This session is designed to facilitate discussion on available data, research gaps, and best practices for evaluating and managing patients with various PCDs who are potential candidates for renal transplantation.

MODERATOR: Naoka Murakami, MD, PhD

2:00 PM **Introduction to the Practice Survey and Best Practices Paper**
Naoka Murakami, MD, PhD

2:20 PM **MGRS**
HEMATOLOGIST: TBA
NEPHROLOGIST: TBA

2:35 PM **Myeloma**
HEMATOLOGIST: TBA
NEPHROLOGIST: Allison Webber, MD

2:50 PM **Amyloid**
HEMATOLOGIST: Heather J. Landau, MD
NEPHROLOGIST: Nelson Leung, MD

3:05 PM **Precursor Conditions**
HEMATOLOGIST: TBA
NEPHROLOGIST: TBA

3:20 PM **Panel Discussion and Q&A**

Novel Therapies and Complications

MODERATOR: Aisha Shaikh, MBBS

3:45 PM **Novel Therapies**
Sham Mailankody, MBBS

4:00 PM **Complications of Novel Therapies**
Aisha Shaikh, MBBS

4:15 PM **Panel Discussion and Q&A**

4:25 PM

Closing Remarks

Heather J. Landau, MD

Adjournment of CME-Accredited Session

4:30 PM

Networking Break with Refreshments in Lobby

NON-ACCREDITED INDUSTRY SESSION

5:00—6:00 PM

Additional details will be announced soon.

Please note that Continuing Medical Education (CME) credits are not available for the non-accredited industry session.

For details and registration, visit:
[msk.org/KidneyTransplantation](https://www.msk.org/KidneyTransplantation)



Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **6.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABS CC RECOGNITION STATEMENT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 6.00 Medical Knowledge MOC Points in the American Board of Internal Medicine's Maintenance of Certification Assessment Recognition program; and
- 6.00 Accredited CME and Self-Assessment MOC points in the American Board of Surgery's Continuous Certification program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABS MOC credit.

An application for NCPD credits has been submitted.



Memorial Sloan Kettering
Cancer Center